The immunohistochemical (IHC) analyses of 2HF treated breast tumors showed decreased levels of proliferation markers Ki67 and PCNA, angiogenesis marker CD31, and increased levels of epithelial differentiation marker E-cadherin (Figure 7) [33]. The gene discussed is MKI67; the disease is breast neoplasm.